Combined inhibition of CTLA4 and PD1 has high activity against brain metastasis and the highest 5-year overall survival rate of all therapies used in advanced melanomas, although immune-related adverse events occur frequently [10]. The gene discussed is CTLA4; the disease is melanoma.